Articles tagged "Hepatitis C"

2020 American Transplant Congress
Hepatitis C-Infected Donors and Hepatitis C-Infected Recipients: Analysis of Renal Transplant Outcomes
H. Crossman¹, M. Tavakol², C. Freise², P. Chin-Hong³
¹Internal Medicine Residency Program, UCSF, San Francisco, CA, ²Surgery, UCSF, San Francisco, CA, ³Infectious Disease, UCSF, San Francisco, CA
*Purpose: Increased utilization of hepatitis C virus infected organs could reduce the supply demand mismatch in organ transplantation. At this time, there is little data…
2020 American Transplant Congress
Re-Transplantation Outcomes in the United States Before and after DAA-Introduction
T. Ivanics, M. Rizzari, A. Al-Kurd, T. Kitajima, A. Elsabbagh, K. Collins, A. Yoshida, M. Abouljoud, S. Nagai
Surgery, Henry Ford Hospital, Detroit, MI
*Purpose: The success of direct-acting antiviral (DAA) therapy has led to the widespread treatment of HCV and near-universal cure for chronically infected patients and improved…
2020 American Transplant Congress
Direct Acting Anti-Viral Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic Donors to Hepatitis C Negative Kideney Transplant Recipients
G. Gupta, I. Yakubu, D. Kumar, I. Moinuddin, L. Kamal, A. King, C. Bhati, A. Sharma, A. Cotterell, A. Khan, M. Levy, R. Sterling
Virginia Commonwealth University, Richmond, VA
*Purpose: Previous trials in kidney transplantation (KT) have described a 12-week course of direct-acting anti-viral drugs (DAA) to treat HCV transmission from infected donors to…
2020 American Transplant Congress
Multi-Center, Open-Label Trial of Pre-Emptive Glecaprevir/Pibrentasvir (G/P) to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus (MYTHIC)
M. Sise¹, D. Goldberg², J. Kort³, D. Schaubel⁴, R. Alloway⁵, C. Durand⁶, R. Fontana⁷, J. Friedewald⁸, R. Brown⁹, S. Prenner¹⁰, R. Landis⁴, P. Reese¹¹, R. Chung¹
¹Internal Medicine - Nephrology, MGH, Boston, MA, ²Hepatology and Transplantation, U Miami, Miami, FL, ³Abbvie, Chicago, IL, ⁴Department of Biostatistics, U Penn, Philadelphia, PA, ⁵Department of Internal Medicine - Nephrology and Hypertension, U Cincinnati, Cincinnati, OH, ⁶Department of Medicine, JHU, Baltimore, MD, ⁷Internal Medicine - Gastroenterology, U Michigan, Ann Arbor, MI, ⁸Internal Medicine - Nephrology and Hypertension, Northwestern, Chicago, IL, ⁹Internal Medicine - Hepatology, Weill Cornell, NYC, NY, ¹⁰Internal Medicine - Gastroenterology, U Penn, Philadelphia, PA, ¹¹Transplant Nephrology, U Penn, Philadelphia, PA
*Purpose: Kidneys from Hepatitis C virus (HCV)-infected deceased donors continue to be discarded at high rates despite small, successful studies of HCV-viremic donors into uninfected…
2020 American Transplant Congress
Utilization of Hepatitis C Positive Organs in Kidney Transplantation
J. Mandel, U. Kaszubski, A. Freeman, L. Hutchinson, M. Janusek, C. Reuter, C. Velasco, B. Wise, S. Anders, E. Bugeaud
Ochsner Medical Center, New Orleans, LA
*Purpose: The efficacy of direct acting antivirals (DAAs) in HCV has cleared the path for the use of HCV positive donor kidneys into negative recipients.…
2020 American Transplant Congress
Solid Organ Transplantation Using Hepatitis C Virus Positive Donor Organs for Hepatitis C Virus Negative Recipients
T. Schiff, R. Bodin, I. Lee, K. Okumura, D. C. Wolf, A. Dhand, A. L. Gass, D. Spielvogel, G. Veillette, S. Nishida, D. Glicklich, K. Wolfe, T. Diflo, H. Sogawa
New York Medical College/ Westchester Medical Center, Valhalla, NY
*Purpose: To determine the effects of transplanting an HCV-positive solid organ to an uninfected patient who is on the transplant waiting list and might otherwise…
2020 American Transplant Congress
Longer-Term Outcomes from the THINKER and EXPANDER Trials of Transplantation Using HCV-Viremic Kidneys
V. S. Potluri¹, F. Naqvi², P. Reese¹, M. Shah¹, D. Brown², S. Prenner¹, A. Loupy³, A. Woodards¹, P. Abt¹, E. Blumberg¹, J. Trofe-Clark¹, D. Segev², R. Bloom¹, D. Sawinski¹, C. Durand², P. Porrett¹, M. Levine¹, D. Goldberg⁴, N. Desai²
¹University of Pennsylvania, Philadelphia, PA, ²Johns Hopkins, Baltimore, MD, ³Paris Transplant Group, Paris, France, ⁴University of Miami, Miami, FL
*Purpose: The practice of transplanting HCV-viremic kidneys into HCV-negative recipients has become more common, but longer-term outcomes have not been reported. We present data on…
2020 American Transplant Congress
Utilization of Hepatitis C Viremic Donors in Liver Transplantation. A Single Center Experience
R. Cohen, N. Chandolias*, K. Khanmoradi, S. Campos, H. Kaul, J. Walter, S. Rossi, V. Navarro, R. Zaki
Department of Digestive Disease and Transplantation, Albert Einstein Medical Center, Philadelphia, PA
*Purpose: The evolution of effective direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV), in the setting of the well recognized organ shortage and the…
2020 American Transplant Congress
Glecaprevir-Pibrentasvir Effect on Tacrolimus Troughs in Abdominal Transplant Recipients
M. Chunduru, K. Schnelle, H. Winters, O. Witkowsky, L. Von Stein
The Ohio State Wexner Medical Center, Columbus, OH
*Purpose: Glecaprevir-pibrentasvir (GP) is one of several pangenotypic therapies available for the treatment of hepatitis C. Historical use of ritonavir based hepatitis C therapies increased…
2019 American Transplant Congress
Development and Characterization of Human-Derived Xenograft Model for Hepatocellular Carcinoma
M. Nazzal¹, R. Steele², R. Ray³, N. Phillips², J. Long⁴, R. Ray²
¹Surgery, Saint Louis University, Saint Louis, MO, ²Pathology, Saint Louis University, Saint Louis, MO, ³Internal Medicine, Saint Louis University, Saint Louis, MO, ⁴Comparative Medicine, Saint Louis University, Saint Louis, MO
*Purpose: Hepatocellular carcinoma (HCC) is rising in the USA and treatment options are limited. There is no convenient animal model for HCC to study novel…